| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.023 | 0.8 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.049 | 0.8 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |